Covigenix VAX-002
/ Entos Pharma, Aegis Life
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 17, 2025
VAX-002-01: To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
(clinicaltrials.gov)
- P1/2 | N=46 | Completed | Sponsor: Entos Pharmaceuticals Inc. | Recruiting ➔ Completed | N=300 ➔ 46 | Trial completion date: Jul 2026 ➔ Oct 2025
Enrollment change • Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 28, 2024
VAX-002-01: To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
(clinicaltrials.gov)
- P1/2 | N=300 | Recruiting | Sponsor: Entos Pharmaceuticals Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG
May 31, 2024
VAX-002-01: To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
(clinicaltrials.gov)
- P1/2 | N=300 | Not yet recruiting | Sponsor: Entos Pharmaceuticals Inc.
New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG
1 to 3
Of
3
Go to page
1